Physician profile
John L Michaelos
NPI 1851353239
$2,523.88
in general payments reported to CMS, 2019-2025
22 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $338 · 2021: $620 · 2022: $289 · 2023: $170 · 2024: $431 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $708.32 | 2019-2025 | Wavelight Refractive Suite, Clareon, Rocklatan |
| Eyevance Pharmaceuticals LLC | $297.22 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $194.05 | 2019-2025 | |
| Dompe US, INC. | $177.35 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $135.80 | 2022-2025 | Miebo, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $130.54 | 2020-2023 | Tecnis Iol |
| Allergan, INC. | $97.06 | 2019-2021 | |
| Ocular Therapeutix, INC. | $91.54 | 2021-2025 | Dextenza |
| Sight Sciences, INC. | $81.50 | 2019-2025 | Sion Surgical Instrument, Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $79.07 | 2022-2023 | Acthar |
| Amgen INC. | $75.76 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $61.31 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.06 | 2020-2021 | |
| Oyster Point Pharma, INC. | $53.32 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $52.33 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $45.25 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $44.61 | 2021 | |
| Aerie Pharmaceuticals, INC. | $44.57 | 2019-2021 | |
| Akorn, INC. | $28.91 | 2020 | |
| Biotissue Holdings INC. | $24.55 | 2025 | |
| Astellas Pharma US INC | $23.76 | 2024 | Izervay |
| Mallinckrodt Enterprises LLC | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Michaelos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.